MedTrace Logo

Continuous Glucose Monitoring in Pregnant Women Undergoing Betamethasone Therapy

NCT01165775 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 17

Last updated 2016-09-16

Study results available
· View outcomes & findings →

Summary

We hope to clarify how betamethasone affects glucose levels in the mother in the days after receiving the drug. This understanding will hopefully allow us to better anticipate the risk of maternal hyperglycemia and therefore establish more appropriate monitoring of maternal glucose to prevent maternal and neonatal complications of hyperglycemia.

Conditions

  • Pregnancy Complications

Interventions

DEVICE

Dexcom Seven Plus Continuous Glucose Monitoring System

Soft sensor for continuous glucose monitoring inserted for up to 24 hours prior to administration of betamethasone. Device to be worn for duration of hospitalization or up to 7 days total, whichever time period is shorter.

Sponsors & Collaborators

Principal Investigators

  • Yasser Yehia El-Sayed · Stanford University

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2014-06-30
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01165775 on ClinicalTrials.gov